Strategic Acquisition Neuravi is now part of the Johnson and Johnson family through Codman Neuro's acquisition, indicating access to a larger corporate distribution, sales networks, and potential to leverage J&J’s global neurology and stroke portfolio to expand market penetration for EmboTrap II in regions beyond Europe.

Regulatory Footprint EmboTrap II is CE marked and commercially available in Europe, with investigational use in the United States, presenting a clear growth path where partnerships with distributors or contract teams could accelerate US IDE or trial activities and later US commercialization.

Clinical Collaboration Active support through the Neuravi Thromboembolic Initiative signals an openness to clinician-researcher collaboration, offering opportunities to co-develop data-driven evidence, real-world outcomes, and key opinion leader engagement to drive adoption among stroke interventionists.

Funding and Scale With funding totaling around $45M and current revenue under $1M, there is an opportunity to position Neuravi’s platform with strategic investors or co-promotional arrangements within a larger medical device portfolio to scale manufacturing, field trials, and reimbursable case volumes.

Targeted Partners The company ecosystem includes potential channel partners and peers in neurovascular fields (e.g., Advant Medical collaborations, and proximity to established manufacturers), suggesting a focused BD approach to identify distributors, OEM partners, and hospital systems that serve stroke centers for accelerated adoption.